Table 2.

Characteristics of studies including systematic review and suggested issues (QIs) for improvement in sentinel node procedures.

Trial	SLN identified	Evaluable pts	FN rate	Tracers	Injection sites	Quality indicators
Veronesi et al., 2010 [17]	100%	516	1.2%	Radiocolloid	Close to the tumor	Wide exclusion criteria
Zavagno et al., 2008 [18]	95%	662	16.7%	Radiocolloid	Subdermally	Wide inclusion criteria
Goyal et al., 2006 [21]	96.1%	842	6.7%	Both dye and radiocolloid	Peritumoral	Dual mapping tracers
Krag et al., 2007 [27]	97.2%	2619	1–17%	Both dye and radiocolloid	Peritumoral	Dual mapping tracers/number of removed nodes
Buonomo et al., 2009 [19]	97.7%	168	3.7%	Radiocolloid	Subdermally/peritumoral	High Risk DCIS treatment Pathologic evaluation protocol
Anan et al., 2006 [23]	96.6%	145	4.9%	Dye	Subareolar/peritumoral	Dual site mapping Dual mapping tracers
Noguchi, 2009 [28]	99.5%	201	8.5%	Both dye and radiocolloid	Subareolar/peritumoral	Dual site mapping Dual mapping tracers
Brenot-Rossi 2003 [25]	90.7%	332	6.6%	Radiocolloid	Subareolar/peritumoral	Failure/negative scintigraphy Unsuccessful mapping/skipping foci
Bourgeois 2008 [29]	90%	521	5–23.8%	Radiocolloid	Subareolar/peritumoral	Unsuccessful mapping Rescue injection technique

SLN: sentinel lymph node; QIs: quality indicator.